[go: up one dir, main page]

HK1117060A1 - Nanoparticulate and controlled release compositions comprising aryl-heterocyclic compounds - Google Patents

Nanoparticulate and controlled release compositions comprising aryl-heterocyclic compounds Download PDF

Info

Publication number
HK1117060A1
HK1117060A1 HK08110215A HK08110215A HK1117060A1 HK 1117060 A1 HK1117060 A1 HK 1117060A1 HK 08110215 A HK08110215 A HK 08110215A HK 08110215 A HK08110215 A HK 08110215A HK 1117060 A1 HK1117060 A1 HK 1117060A1
Authority
HK
Hong Kong
Prior art keywords
nanoparticulate
ziprasidone
aryl
controlled release
heterocyclic compounds
Prior art date
Application number
HK08110215A
Other languages
Chinese (zh)
Inventor
Devane John
Stark Paul
Fanning Niall
Rekhi Gurvinder
Jenkins Scott
Liversidge Gary
Original Assignee
Elan Pharma International Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/372,857 external-priority patent/US20060240105A1/en
Application filed by Elan Pharma International Limited filed Critical Elan Pharma International Limited
Publication of HK1117060A1 publication Critical patent/HK1117060A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention provides a composition comprising ziprasidone useful in the treatment and prevention of schizophrenia and similar psychiatric disorders. In one embodiment, the composition comprises nanoparticulate particles comprising ziprasidone and at least one surface stabilizer. The nanoparticulate particles have an effective average particle size of less than about 2000 nm. In another embodiment, the composition comprises a modified release composition that, upon administration to a patient, delivers ziprasidone in a bimodal, multimodal or continuous manner. The invention also relates to dosage forms containing such compositions, and to methods for the treatment and prevention of schizophrenia and similar psychiatric disorders.
HK08110215A 2005-06-20 2006-06-19 Nanoparticulate and controlled release compositions comprising aryl-heterocyclic compounds HK1117060A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US69209605P 2005-06-20 2005-06-20
US60/692,096 2005-06-20
US11/372,857 US20060240105A1 (en) 1998-11-02 2006-03-10 Multiparticulate modified release composition
US11/372,857 2006-03-10
PCT/US2006/023695 WO2007027273A1 (en) 2005-06-20 2006-06-19 Nanoparticulate and controlled release compositions comprising aryl-heterocyclic compounds

Publications (1)

Publication Number Publication Date
HK1117060A1 true HK1117060A1 (en) 2009-01-09

Family

ID=37809174

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08110215A HK1117060A1 (en) 2005-06-20 2006-06-19 Nanoparticulate and controlled release compositions comprising aryl-heterocyclic compounds

Country Status (12)

Country Link
EP (1) EP1901722A4 (en)
KR (1) KR20080024206A (en)
CN (1) CN101879140A (en)
AU (1) AU2006285349A1 (en)
BR (1) BRPI0612297A2 (en)
CA (1) CA2613474A1 (en)
EA (1) EA200800092A1 (en)
HK (1) HK1117060A1 (en)
IL (1) IL188093A0 (en)
NO (1) NO20076628L (en)
SG (1) SG162811A1 (en)
WO (1) WO2007027273A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010009844A (en) * 2008-03-07 2010-09-30 Pfizer Methods, dosage forms, and kits for administering ziprasidone without food.
DE102008045854A1 (en) 2008-09-05 2010-03-11 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Particles of ziprasidone and a disintegrant containing pharmaceutical composition
WO2010082855A1 (en) * 2009-01-15 2010-07-22 Zaklady Farmaceutyczne Polpharma Sa Pharmaceutical compositions comprising ziprasidone free base or ziprasidone hydrochloride and the method for their preparation
WO2011148253A2 (en) 2010-05-25 2011-12-01 Aurobindo Pharma Limited Solid dosage forms of antipsychotics
MX2016007786A (en) 2013-12-16 2017-03-03 Massachusetts Inst Technology Fortified micronutrient salt formulations.
AU2014364930B2 (en) 2013-12-16 2017-06-15 Massachusetts Institute Of Technology Micromolded or 3-D printed pulsatile release vaccine formulations
MA41611A (en) * 2015-02-23 2018-01-02 Omthera Pharmaceuticals Inc MILLI-CAPSULE PREPARATIONS CONTAINING FREE POLYINSATURATED FATTY ACIDS
US12390537B2 (en) 2020-05-13 2025-08-19 Massachusetts Institute Of Technology Compositions of polymeric microdevices and methods of use thereof in cancer immunotherapy

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
NZ248813A (en) * 1992-11-25 1995-06-27 Eastman Kodak Co Polymeric grinding media used in grinding pharmaceutical substances
US6150366A (en) * 1998-06-15 2000-11-21 Pfizer Inc. Ziprasidone formulations
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
RU2236847C2 (en) * 1998-11-02 2004-09-27 Илан Корпорейшн, Плк. Composition as multiple particles with modified release
DK1181018T3 (en) * 1999-05-27 2003-04-22 Pfizer Prod Inc Ziprasidone suspension
MXPA05002561A (en) * 2002-10-25 2005-05-05 Pfizer Prod Inc Novel injectable depot formulations.
AR046811A1 (en) * 2003-09-02 2005-12-28 Imran Ahmed ORAL DOSAGE FORMS OF ZIPRASIDONE OF SUSTAINED LIBERATION
CA2605153A1 (en) * 2005-04-13 2006-10-19 Jaymin Chandrakant Shah Injectable depot formulations and methods for providing sustained release of nanoparticle compositions

Also Published As

Publication number Publication date
AU2006285349A1 (en) 2007-03-08
EP1901722A1 (en) 2008-03-26
CN101879140A (en) 2010-11-10
SG162811A1 (en) 2010-07-29
KR20080024206A (en) 2008-03-17
CA2613474A1 (en) 2007-03-08
BRPI0612297A2 (en) 2010-11-03
NO20076628L (en) 2008-03-12
EP1901722A4 (en) 2011-06-15
EA200800092A1 (en) 2008-06-30
WO2007027273A1 (en) 2007-03-08
IL188093A0 (en) 2008-03-20

Similar Documents

Publication Publication Date Title
NZ573555A (en) Nanoparticulate posaconazole formulations
WO2007086914A3 (en) Nanoparticulate clopidogrel formulations
HUE040393T2 (en) Formulations comprising nanoparticulate meloxicam
SG161203A1 (en) Nanoparticulate tacrolimus formulations
WO2007053197A3 (en) Nanoparticulate acetaminophen formulations
WO2006110809A3 (en) Nanoparticulate lipase inhibitor formulations
BRPI0705488A (en) stable nanoparticulate composition, methods of preparing it and preventing and / or treating a bacterial infection, pharmaceutical composition, and dosage form
WO2007035348A3 (en) Nanoparticulate aripiprazole formulations
ATE457718T1 (en) STERILE FILTERED NANOPARTICLE FORMULATIONS OF BUDESONIDE WITH TYLOXAPOL AS SURFACE STABILIZER
CY1107810T1 (en) COMPOSITIONS WHICH HAVE A COMBINATION OF IMMEDIATE LIBERATION AND CONTROLLED LIBERTY CHARACTERISTICS
NO20076628L (en) Controlled release nanoparticulate compositions comprising arylheterocyclic compounds
WO2008089310A3 (en) Delta 5 desaturase inhibitors for the treatment of obesity
WO2006133046A3 (en) Nanoparticulate imatinib mesylate formulations
WO2007150075A3 (en) Compositions comprising nanoparticulate meloxicam and controlled release hydrocodone
NO20080202L (en) Nanoparticulate clopidogrel and aspirin combination formulations
EP2481402A3 (en) Nanoparticle comprising rapamycin and albumin as anticancer agent
EA200701997A1 (en) COMPOSITION OF BISPHOSPHONATE NANOPARTICLES
ATE419835T1 (en) NYSTATIN NANOPARTICLE COMPOSITIONS
EA200701442A1 (en) COMPOSITIONS OF KANDESARTANA NANOPARTICLES
EP1546099A4 (en) 3,6-disubstituted azabicyclo 3.1.0 hexane derivatives useful as muscarinic receptor antagonists
MX2010009866A (en) Nanoparticulate compositions of angiogenesis inhibitors.
WO2007146943A3 (en) Nanoparticulate kinase inhibitor formulations
WO2008030209A3 (en) Nanoparticulate and controlled release compositions comprising a platelet aggregation inhibitor
WO2006135689A3 (en) Nanoparticulate ebastine formulations
WO2006138421A3 (en) Nanoparticulate azelnidipine formulations